Download MendeleyDiscovery and Characterization of a Chemical Probe Targeting the Zinc-Finger Ubiquitin-Binding Domain of HDAC6.
Harding, R.J., Franzoni, I., Mann, M.K., Szewczyk, M.M., Mirabi, B., Ferreira de Freitas, R., Owens, D.D.G., Ackloo, S., Scheremetjew, A., Juarez-Ornelas, K.A., Sanichar, R., Baker, R.J., Dank, C., Brown, P.J., Barsyte-Lovejoy, D., Santhakumar, V., Schapira, M., Lautens, M., Arrowsmith, C.H.(2023) J Med Chem 66: 10273-10288
- PubMed: 37499118
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00314
- Primary Citation of Related Structures:
8G43, 8G44, 8G45 - PubMed Abstract:
Histone deacetylase 6 (HDAC6) inhibition is an attractive strategy for treating numerous cancers, and HDAC6 catalytic inhibitors are currently in clinical trials. The HDAC6 zinc-finger ubiquitin-binding domain (UBD) binds free C-terminal diglycine motifs of unanchored ubiquitin polymer chains and protein aggregates, playing an important role in autophagy and aggresome assembly. However, targeting this domain with small molecule antagonists remains an underdeveloped avenue of HDAC6-focused drug discovery. We report SGC-UBD253 ( 25 ), a chemical probe potently targeting HDAC6-UBD in vitro with selectivity over nine other UBDs, except for weak USP16 binding. In cells, 25 is an effective antagonist of HDAC6-UBD at 1 μM, with marked proteome-wide selectivity. We identified SGC-UBD253N ( 32 ), a methylated derivative of 25 that is 300-fold less active, serving as a negative control. Together, 25 and 32 could enable further exploration of the biological function of the HDAC6-UBD and investigation of the therapeutic potential of targeting this domain.
Organizational Affiliation:
Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
